Therapeutic Potential of Functional Selectivity in the Treatment of Heart Failure

Trends in Cardiovascular Medicine

Volumn 20, Issue 7, 2010, Pages 221-227

  Christensen, Gitte Lund ^a   Aplin, Mark ^b   Hansen, Jakob Lerche ^c,d  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CARVEDILOL; GUANINE NUCLEOTIDE BINDING PROTEIN;

ANTIHYPERTENSIVE ACTIVITY; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE REGULATION; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; FUNCTIONAL SELECTIVITY; HEART FAILURE; HEART PROTECTION; HUMAN; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; HEART FAILURE; HUMANS; LIGANDS; MICE; MICE, TRANSGENIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84856341963     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2011.11.005     Document Type: Review

References (57)

1. Ahn S., Kim J., Hara M.R., et al. β-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem 2009, 284:8855-8865.
2. Ahn S., Shenoy S.K., Wei H., Lefkowitz R.J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 2004, 279:35518-35525.
3. Ainscough J.F., Drinkhill M.J., Sedo A., et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009, 81:592-600.
4. Allen J.A., Roth B.L. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2011, 51:117-144.
5. Anthony D.F., Sin Y.Y., Vadrevu S., et al. β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol 2011, 31:1066-1075.
6. Aplin M., Bonde M.M., Hansen J.L. Molecular determinants of angiotensin II type 1 receptor functional selectivity. J Mol Cell Cardiol 2009, 46:15-24.
7. Aplin M., Christensen G.L., Schneider M., et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and Langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 2007, 100:289-295.
8. Aplin M., Christensen G.L., Schneider M., et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 2007, 100:296-301.
9. Askoxylakis V., Thieke C., Pleger S.T., et al. Long-term survival of cancer patients compared to heart failure and stroke: A systematic review. BMC Cancer 2010, 10:105.
10. Billet S., Bardin S., Verp S., et al. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007, 117:1914-1925.
11. Black J.W., Leff P. Operational models of pharmacological agonism. Proc R Soc London B Biol Sci 1983, 220:141-162.
12. Boerrigter G., Lark M.W., Whalen E.J., et al. Cardiorenal actions of TRV120027, a novel, β-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011, 4:770-778.
13. Christensen G.L., Kelstrup C.D., Lyngso C., et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 2010, 9:1540-1553.
14. Daaka Y., Luttrell L.M., Lefkowitz R.J. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
15. Daniels D., Yee D.K., Faulconbridge L.F., Fluharty S.J. Divergent behavioral roles of angiotensin receptor intracellular signaling cascades. Endocrinology 2005, 146:5552-5560.
16. DeWire S.M., Kim J., Whalen E.J., et al. Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem 2008, 283:10611-10620.
17. Esposito G., Perrino C., Cannavo A., et al. EGFR trans-activation by urotensin II receptor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res Cardiol 2011, 106:577-589.
18. Evans B.A., Broxton N., Merlin J., et al. Quantification of functional selectivity at the human alpha(1A)-adrenoceptor. Mol Pharmacol 2011, 79:298-307.
19. Fan G., Jiang Y.P., Lu Z., et al. A transgenic mouse model of heart failure using inducible Gαq. J Biol Chem 2005, 280:40337-40346.
20. Frishman W.H., Saunders E. β-Adrenergic blockers. J Clin Hypertens 2011, 13:649-653.
21. Gaborik Z., Jagadeesh G., Zhang M., et al. The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling. Endocrinology 2003, 144:2220-2228.
22. Galandrin S., Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 2006, 70:1575-1584.
23. Godin C.M., Ferguson S.S. The angiotensin II type 1 receptor induces membrane blebbing by coupling to Rho A, Rho kinase, and myosin light chain kinase. Mol Pharmacol 2010, 77:903-911.
24. Gorre F., Vandekerckhove H. Beta-blockers: Focus on mechanism of action. Which beta-blocker, when and why?. Acta Cardiol 2010, 65:565-570.
25. Hansen J.L., Aplin M., Hansen J.T., et al. The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation. Eur J Pharmacol 2008, 590:255-263.
26. Harris D.M., Cohn H.I., Pesant S., et al. Vascular smooth muscle G(q) signaling is involved in high blood pressure in both induced renal and genetic vascular smooth muscle-derived models of hypertension. Am J Physiol Heart Circ Physiol 2007, 293:H3072-H3079.
27. Holloway A.C., Qian H., Pipolo L., et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 2002, 61:768-777.
28. Hunton D.L., Barnes W.G., Kim J., et al. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol 2005, 67:1229-1236.
29. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
30. Kenakin T.P. '7TM receptor allostery: Putting numbers to shapeshifting proteins. Trends Pharmacol Sci 2009, 30:460-469.
31. Kendall R.T., Luttrell L.M. Diversity in arrestin function. Cell Mol Life Sci 2009, 66:2953-2973.
32. Kim I.M., Tilley D.G., Chen J., et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 2008, 105:14555-14560.
33. Lohse M.J., Engelhardt S., Danner S., Bohm M. Mechanisms of beta-adrenergic receptor desensitization: From molecular biology to heart failure. Basic Res Cardiol 1996, 91(Suppl 2):29-34.
34. Mangmool S., Shukla A.K., Rockman H.A. β-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after β(1)-adrenergic receptor stimulation. J Cell Biol 2010, 189:573-587.
35. McPherson J., Rivero G., Baptist M., et al. μ-Opioid receptors: Correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 2010, 78:756-766.
36. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: Results from the COMET trial. Eur Heart J 2005, 26:2259-2268.
37. Noma T., Lemaire A., Naga Prasad S.V., et al. β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007, 117:2445-2458.
38. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003, 362:7-13.
39. Rajagopal S., Ahn S., Rominger D.H., et al. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 2011, 80:367-377.
40. Sadoshima J., Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: Critical role of the AT1 receptor subtype. Circ Res 1993, 73:413-423.
41. 2+ in cardiac myocytes. Biophys J 2008, 95:4597-4612.
42. Seta K., Nanamori M., Modrall J.G., et al. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 2002, 277:9268-9277.
43. 2+-calmodulin targets. J Biol Chem 2008, 283:31531-31540.
44. Stewart S., MacIntyre K., Hole D.J., et al. More "malignant" than cancer?. Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001, 3:315-322.
45. Tilley D.G., Nguyen A.D., Rockman H.A. Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochem Biophys Res Commun 2010, 396:921-926.
46. Urban J.D., Clarke W.P., von Zastrow M., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
47. Verdecchia P., Angeli F., Cavallini C., et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: A meta-analysis. Eur Heart J 2009, 30:679-688.
48. Violin J.D., DeWire S.M., Yamashita D., et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010, 335:572-579.
49. 2+/calmodulin kinase signaling pathway. Circ Res 2004, 95:798-806.
50. Wei H., Ahn S., Shenoy S.K., et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 2003, 100:10782-10787.
51. α11 in cardiomyocytes. Nat Med 2001, 7:1236-1240.
52. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 2011, 17:126-139.
53. Wisler J.W., DeWire S.M., Whalen E.J., et al. A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 2007, 104:16657-16662.
54. Xiao K., Sun J., Kim J., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci USA 2010, 107:15299-15304.
55. Yoo B., Lemaire A., Mangmool S., et al. β1-Adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2009, 297:H1377-H1386.
56. αi coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005, 115:3045-3056.
57. Zhang T., Maier L.S., Dalton N.D., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 2003, 92:912-919.